Diagnosis of cancer by detecting auto-antibodies against vascular endothelial growth factor (vegf)
AssigneeCelltrend GmbH
InventorsHarald HEIDECKE, Kai SCHULZE-FORSTER
Life of this patent
Estimating the term…
Loading patent…
AssigneeCelltrend GmbH
InventorsHarald HEIDECKE, Kai SCHULZE-FORSTER
Estimating the term…
The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor (VEGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.
A method for diagnosis of cancer, comprising
A method for diagnosis of cancer, wherein the level of antibodies against vascular endothelial growth factor (VEGF) is determined in a sample from a subject to be diagnosed and wherein a level of anti-VEGF antibodies below 14 units/ml is indicative for cancer.
A method for predicting whether a subject to be treated for cancer with a drug will respond to said treatment comprising
A method for the prediction of risk stratification for relapse of cancer and/or mortality in a patient to be treated or being treated for cancer with a drug, the method comprising
An immunoassay method for detecting an anti-VEGF antibody in a sample from a subject, comprising
VEGF or an antigenic peptide fragment thereof for diagnosis of cancer or for prediction of response of a subject suffering from cancer and to treatment with a drug, or for prediction of relapse and/or mortality of a subject suffering from cancer and to be treated with a drug.
An angiogenesis inhibitor for use in the treatment of cancer in a subject, wherein the angiogenesis inhibitor is administered when the level anti-VEGF antibodies in a sample from the subject is above 8 units/ml.
A kit for diagnosing cancer, or predicting response of a cancer patient to treatment with an angiogenesis inhibitor or a chemotherapeutic drug, said kit comprising VEGF or an antigenic peptide thereof, and means to detect antibodies binding to said VEGF or peptide thereof.
Dependencies are inferred from the claim text.